Category: CBSA News

For Immediate Release: February 27, 2024 NEWS RELEASE 20+ Life Sciences Organizations, Economic Development Groups, Local Governments, Developers, and Builders Invest to Bring New, High-Growth Compani...

On Friday, February 23, the Colorado Prescription Drug Affordability Board (PDAB or Board) decided to initiate an “upper payment limit” (UPL) rulemaking process for the autoimmune disease drug Enbrel...

On Friday, February 16, the Colorado Prescription Drug Affordability Board (PDAB or Board) completed its second and third affordability reviews, following its first decision on December 8 that the cys...

The first few weeks of the Colorado legislative session require intensive engagement at the Capitol and comprehensive review of proposed legislation by CBSA's Policy + Advocacy team to support a colla...

A look at the accomplishments, progress, and innovation behind the buzz. At Fitzsimons Innovation Community, we know January is one of the best times to look forward, set goals, and make plans for the...

CBSA urges you to take action now to protect America’s innovation economy! The federal government is considering the use of “march-in rights” (where it could compel a patent-owner to license an invent...

CBSA and our partners at BIO urge you to act now! Encourage members of Congress to pass a tax package before the end of January that includes restoration of immediate R&D expensing to protect our...

Colorado’s 2024 legislative session kicked off on Wednesday, January 10th, and will continue for 120 days until May 8th.   The Legislature: For the sixth year, Democrats have total control o...

Colorado BioScience Association (CBSA) has released its 2023 CBSA Policy + Advocacy Report, which summarizes CBSA’s engagement during the Colorado legislative session, the regulatory process to implem...

Back in December of 2013, Jian Zhang, Ph.D. and Founder and CEO of Z Biotech, was doing advanced research in glycobiology and just starting his company. He was a one-man show, and, in 2014, opened wit...